Krakauer H
Eur J Clin Microbiol. 1985 Feb;4(1):1-9. doi: 10.1007/BF02148651.
This review highlights the properties, problems, and potentials of monoclonal antibodies as diagnostic and therapeutic agents. The most extensive experience has been obtained with antibodies specific for functionally distinct subsets of lymphocytes. They have been used to monitor the immunosuppression of organ-graft recipients and to attempt to elucidate the disturbance of immunologic function in a variety of conditions. Current therapeutic applications under trial include immunosuppression to treat organ-graft rejection and to eliminate cells responsible for graft-vs-host disease from the bone marrow. Applications to cancer diagnosis and treatment have been hampered by the difficulty of identifying truly tumor-specific antigens. Successes have, however, been obtained in the location of metastases and in the extracorporeal treatment of autologous marrow to purge it of malignant cells, and, more rarely, with the direct administration of monoclonal antibodies in vivo. The conjugation of cell-type specific monoclonal antibodies with cytotoxic agents should overcome a number of limitations.
本综述重点介绍了单克隆抗体作为诊断和治疗剂的特性、问题及潜力。在针对功能不同的淋巴细胞亚群的特异性抗体方面积累了最为丰富的经验。它们已被用于监测器官移植受者的免疫抑制情况,并试图阐明各种病症中免疫功能的紊乱。目前正在试验的治疗应用包括用于治疗器官移植排斥反应的免疫抑制,以及从骨髓中清除引发移植物抗宿主病的细胞。由于难以鉴定真正的肿瘤特异性抗原,单克隆抗体在癌症诊断和治疗中的应用受到了阻碍。然而,在转移灶定位以及体外处理自体骨髓以清除其中的恶性细胞方面已取得成功,而且在体内直接施用单克隆抗体的情况则较为少见。将细胞类型特异性单克隆抗体与细胞毒性剂结合应能克服一些限制。